Publication:
Does Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms

dc.contributor.authorLekovic, Danijela (36659562000)
dc.contributor.authorIvanovic, Jelena (58551445800)
dc.contributor.authorTerzic, Tatjana (55916182400)
dc.contributor.authorPerunicic Jovanovic, Maja (57210906777)
dc.contributor.authorDencic Fekete, Marija (15836938800)
dc.contributor.authorJovanovic, Jelica (57202914654)
dc.contributor.authorArsenovic, Isidora (58551558700)
dc.contributor.authorVukovic, Vojin (56180315400)
dc.contributor.authorBila, Jelena (57208312102)
dc.contributor.authorBogdanovic, Andrija (6603686934)
dc.contributor.authorAntic, Darko (23979576100)
dc.date.accessioned2025-06-12T11:47:35Z
dc.date.available2025-06-12T11:47:35Z
dc.date.issued2024
dc.description.abstractBackground: The occurrence of myeloproliferative neoplasms (MPNs) that evolve into each other is well-described, as is this occurrence of lymphoproliferative neoplasms (LPNs). However, less is known about rare MPN/LPN coexistence, and the aim of our study was to analyze charachteristics of these patients after long term follow-up. Methods: Fourteen patients with MPN/LPN coexistence were diagnosed and treated according to guidelines at a single university center across two decades. Results: The overall median age was 53 years (22–69). MPNs patients with subsequent LPNs had a shorter period of second malignancy development and a more aggressive course of LPN, which can cause fatal outcomes. Polycythemia vera and chronic lymphocytic leukemia were most commonly associated (36%). The JAK2V617F mutation had 2/3 and cytogenetic abnormalities occurred in 1/3 of patients. MPN/LPN coexistence cases had significantly higher thrombotic potential (42.8%) and a higher third malignancy accruement frequency (21.4%) versus those without such malignancies. Conclusions: Considering the younger ages at MPN diagnosis, it is recommended to check regularly for blood lymphocytosis or lymphadenopathy occurrences and organomegaly progression faster than expected for MPN, with the aim of timely LPN diagnoses. The presence of molecular-cytogenetic abnormalities in a majority of patients indicate possible genetic instability and increased risk of development of multiple neoplasms, thus elevating thrombotic risk. © 2024 by the authors.
dc.identifier.urihttps://doi.org/10.3390/jcm13061816
dc.identifier.urihttps://www.scopus.com/inward/record.uri?eid=2-s2.0-85189002855&doi=10.3390%2fjcm13061816&partnerID=40&md5=47cbd6c6f0b2acf90e6243453a3b7d02
dc.identifier.urihttps://remedy.med.bg.ac.rs/handle/123456789/1239
dc.subjectlymphoproliferative neoplasm
dc.subjectmyeloproliferative neoplasm
dc.subjectprognosis
dc.subjectsurvival
dc.subjectthrombosis
dc.titleDoes Double Mean Trouble? Coexistence of Myeloproliferative and Lymphoproliferative Neoplasms
dspace.entity.typePublication

Files